vs
Esperion Therapeutics, Inc.（ESPR）与HIVE Digital Technologies Ltd.（HIVE）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是HIVE Digital Technologies Ltd.的1.8倍（$168.4M vs $93.1M），HIVE Digital Technologies Ltd.同比增速更快（218.6% vs 143.7%），过去两年HIVE Digital Technologies Ltd.的营收复合增速更高（102.2% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
该企业是一家数字化转型与信息技术服务公司，总部位于宾夕法尼亚州匹兹堡，业务覆盖北美、中东、亚洲以及日本地区，为各行各业的企业客户提供专业的IT相关服务支持。
ESPR vs HIVE — 直观对比
营收规模更大
ESPR
是对方的1.8倍
$93.1M
营收增速更快
HIVE
高出74.8%
143.7%
两年增速更快
HIVE
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $93.1M |
| 净利润 | — | $-91.3M |
| 毛利率 | — | -27.1% |
| 营业利润率 | 50.6% | — |
| 净利率 | — | -98.1% |
| 营收同比 | 143.7% | 218.6% |
| 净利润同比 | — | -234.0% |
| 每股收益（稀释后） | $0.32 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRHIVE
| Q4 25 | $168.4M | $93.1M | ||
| Q3 25 | $87.3M | $87.3M | ||
| Q2 25 | $82.4M | $45.6M | ||
| Q1 25 | $65.0M | — | ||
| Q4 24 | $69.1M | $29.2M | ||
| Q3 24 | $51.6M | $22.6M | ||
| Q2 24 | $73.8M | $32.2M | ||
| Q1 24 | $137.7M | — |
净利润ESPRHIVE
| Q4 25 | — | $-91.3M | ||
| Q3 25 | $-31.3M | $-15.8M | ||
| Q2 25 | $-12.7M | $35.0M | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | — | $68.2M | ||
| Q3 24 | $-29.5M | $80.0K | ||
| Q2 24 | $-61.9M | $-18.3M | ||
| Q1 24 | $61.0M | — |
毛利率ESPRHIVE
| Q4 25 | — | -27.1% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | -13.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -43.7% | ||
| Q3 24 | — | -66.1% | ||
| Q2 24 | — | -7.4% | ||
| Q1 24 | — | — |
营业利润率ESPRHIVE
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
净利率ESPRHIVE
| Q4 25 | — | -98.1% | ||
| Q3 25 | -35.9% | -18.1% | ||
| Q2 25 | -15.4% | 76.8% | ||
| Q1 25 | -62.2% | — | ||
| Q4 24 | — | 233.2% | ||
| Q3 24 | -57.2% | 0.4% | ||
| Q2 24 | -83.9% | -56.7% | ||
| Q1 24 | 44.3% | — |
每股收益（稀释后）ESPRHIVE
| Q4 25 | $0.32 | $-0.38 | ||
| Q3 25 | $-0.16 | $-0.07 | ||
| Q2 25 | $-0.06 | $0.18 | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | $0.52 | ||
| Q3 24 | $-0.15 | $0.00 | ||
| Q2 24 | $-0.33 | $-0.17 | ||
| Q1 24 | $0.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $559.3M |
| 总资产 | $465.9M | $624.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRHIVE
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | $40.5M | ||
| Q3 24 | $144.7M | $31.7M | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
股东权益ESPRHIVE
| Q4 25 | $-302.0M | $559.3M | ||
| Q3 25 | $-451.4M | $624.6M | ||
| Q2 25 | $-433.5M | $560.5M | ||
| Q1 25 | $-426.2M | — | ||
| Q4 24 | $-388.7M | $430.9M | ||
| Q3 24 | $-370.2M | $275.5M | ||
| Q2 24 | $-344.2M | $268.6M | ||
| Q1 24 | $-294.3M | — |
总资产ESPRHIVE
| Q4 25 | $465.9M | $624.0M | ||
| Q3 25 | $364.0M | $693.0M | ||
| Q2 25 | $347.1M | $628.7M | ||
| Q1 25 | $324.0M | — | ||
| Q4 24 | $343.8M | $478.6M | ||
| Q3 24 | $314.1M | $334.7M | ||
| Q2 24 | $352.3M | — | ||
| Q1 24 | $373.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $46.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRHIVE
| Q4 25 | $45.2M | $46.0M | ||
| Q3 25 | $-4.3M | $-10.6M | ||
| Q2 25 | $-31.4M | $10.2M | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $-35.0M | $-28.5M | ||
| Q3 24 | $-35.3M | $-2.2M | ||
| Q2 24 | $-7.2M | $-4.4M | ||
| Q1 24 | $53.8M | — |
自由现金流ESPRHIVE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-55.5M | ||
| Q3 24 | $-35.5M | $-34.7M | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
自由现金流率ESPRHIVE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -189.9% | ||
| Q3 24 | -68.7% | -153.4% | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
资本支出强度ESPRHIVE
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 92.5% | ||
| Q3 24 | 0.3% | 143.9% | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率ESPRHIVE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.42× | ||
| Q3 24 | — | -26.94× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
HIVE
暂无分部数据
